CompletedNot Applicable

Bicentric Study on the Use of ECMO-VV or VA for Severe ARDS Associated With Covid-19

France50 participantsStarted 2020-06-18

Plain-language summary

Describes the cohort of patients receiving ECMO-VV or ECMO-VA in the management of severe ARDS refractory to SARS-CoV-2 in the Strasbourg and Louvain centres

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patient over the age of 18; * Diagnostic COVID-19 by RT-PCR; * Hospitalisation in resuscitation for the management of complications related to COVID-19 * Implanted ECMO-VV or VA during hospitalisation; * Patient agreeing to participate in the study Exclusion Criteria: * Sujet who has expressed opposition to participating in the study. * Sujet under guardianship or trusteeship * Sujet under safeguard of justice

What they're measuring

Retrospective description of effect of the ECMO-VV or ECMO-VA in the management of severe ARDS refractory in patients of the Strasbourg and Louvain centres with covid-19

Timeframe: files analysed retrospectily from March 1st, 2020 to August 1st, 2020 will be examined

Trial details

NCT IDNCT04446286

SponsorUniversity Hospital, Strasbourg, France

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2020-08-18

View on ClinicalTrials.gov More Covid-19 trials